Literature DB >> 16186247

Prion clearance in bigenic mice.

Jiri G Safar1,2, Stephen J DeArmond3,2, Katarzyna Kociuba2, Camille Deering2, Svetlana Didorenko2, Essia Bouzamondo-Bernstein3, Stanley B Prusiner4,1,2, Patrick Tremblay1,2.   

Abstract

The clearance of prions from the brain was investigated in bigenic mice designated Tg(tTA : PrP(+/0))3, in which expression of the cellular prion protein (PrP(C)) was regulated by oral doxycycline administration. With suppression of PrP(C) expression, the incubation time for RML prions was prolonged almost threefold from approximately 150 to approximately 430 days. To determine the clearance rate of disease-causing PrP(Sc), bigenic mice were given oral doxycycline beginning 98 days after inoculation with RML prions and sacrificed at various time points over the subsequent 56 days. The half-life (t1/2) for PrP(Sc) was approximately 1.5 days in mouse brain, in reasonable agreement with the apparent t1/2 of 30 h that was determined in a separate study for scrapie-infected mouse neuroblastoma (ScN2a) cells in culture. Both protease-sensitive and -resistant conformers of PrP(Sc) were cleared at the same rate. The t1/2 value for PrP(C) clearance from brain was approximately 18 h, which was considerably longer than the t1/2 of 5 h found in ScN2a cells. The capability of the brain to clear prions raises the possibility that PrP(Sc) is normally made at low levels and continually cleared, and that PrP(Sc) may have a function in cellular metabolism. Moreover, these bigenic mice make it possible to determine both components of PrP(Sc) accumulation, i.e. the rates of formation and clearance, for various strains of prions exhibiting different incubation times.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186247     DOI: 10.1099/vir.0.80947-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  73 in total

Review 1.  Prions.

Authors:  David W Colby; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

2.  Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development.

Authors:  Sonia M Vallabh; Chloe K Nobuhara; Franc Llorens; Inga Zerr; Piero Parchi; Sabina Capellari; Eric Kuhn; Jacob Klickstein; Jiri G Safar; Flavia C Nery; Kathryn J Swoboda; Michael D Geschwind; Henrik Zetterberg; Steven E Arnold; Eric Vallabh Minikel; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-01       Impact factor: 11.205

3.  Formation of native prions from minimal components in vitro.

Authors:  Nathan R Deleault; Brent T Harris; Judy R Rees; Surachai Supattapone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

4.  Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.

Authors:  Marcela V Karpuj; Kurt Giles; Sagit Gelibter-Niv; Michael R Scott; Vishwanath R Lingappa; Francis C Szoka; David Peretz; Wilfred Denetclaw; Stanley B Prusiner
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

5.  Mechanisms of prion protein assembly into amyloid.

Authors:  Jan Stöhr; Nicole Weinmann; Holger Wille; Tina Kaimann; Luitgard Nagel-Steger; Eva Birkmann; Giannantonio Panza; Stanley B Prusiner; Manfred Eigen; Detlev Riesner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

6.  A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner.

Authors:  Young Pyo Choi; Suzette A Priola
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

7.  Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

Authors:  Eric Vallabh Minikel; Eric Kuhn; Alexandra R Cocco; Sonia M Vallabh; Christina R Hartigan; Andrew G Reidenbach; Jiri G Safar; Gregory J Raymond; Michael D McCarthy; Rhonda O'Keefe; Franc Llorens; Inga Zerr; Sabina Capellari; Piero Parchi; Stuart L Schreiber; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2019-09-26       Impact factor: 5.911

8.  Prion formation, but not clearance, is supported by protein misfolding cyclic amplification.

Authors:  Ronald A Shikiya; Thomas E Eckland; Alan J Young; Jason C Bartz
Journal:  Prion       Date:  2014       Impact factor: 3.931

9.  Prion disease tempo determined by host-dependent substrate reduction.

Authors:  Charles E Mays; Chae Kim; Tracy Haldiman; Jacques van der Merwe; Agnes Lau; Jing Yang; Jennifer Grams; Michele A Di Bari; Romolo Nonno; Glenn C Telling; Qingzhong Kong; Jan Langeveld; Debbie McKenzie; David Westaway; Jiri G Safar
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

10.  Chemical induction of misfolded prion protein conformers in cell culture.

Authors:  Sina Ghaemmaghami; Julie Ullman; Misol Ahn; Susan St Martin; Stanley B Prusiner
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.